These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28079593)

  • 1. Improving the clinic-laboratory-interface in the context of HIV diagnosis, treatment, and monitoring.
    Tucker TJ; Manyike PT
    Curr Opin HIV AIDS; 2017 Mar; 12(2):105-111. PubMed ID: 28079593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving laboratory efficiencies to scale-up HIV viral load testing.
    Alemnji G; Onyebujoh P; Nkengasong JN
    Curr Opin HIV AIDS; 2017 Mar; 12(2):165-170. PubMed ID: 28059956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation science: the laboratory as a command centre.
    Boeras DI; Nkengasong JN; Peeling RW
    Curr Opin HIV AIDS; 2017 Mar; 12(2):171-174. PubMed ID: 28079592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory monitoring of HIV/AIDS in a resource-poor setting.
    Glencross DK; Mendelow BV; Stevens WS
    S Afr Med J; 2003 Apr; 93(4):262-3. PubMed ID: 12806710
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
    Bélec L; Bonn JP
    Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV viral load scale-up: multiple interventions to meet the HIV treatment cascade.
    Carmona S; Peter T; Berrie L
    Curr Opin HIV AIDS; 2017 Mar; 12(2):157-164. PubMed ID: 28134713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing.
    Scott LE; Carmona S; Gous N; Horsfield P; Mackay M; Stevens W
    J Clin Microbiol; 2012 Dec; 50(12):4083-6. PubMed ID: 22993182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize HIV treatment outcomes in resource-limited settings.
    Nakanjako D; Colebunders R; Coutinho AG; Kamya MR
    AIDS Rev; 2009; 11(4):179-89. PubMed ID: 19940945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings.
    Stevens WS; Scott LE; Crowe SM
    J Infect Dis; 2010 Apr; 201 Suppl 1():S16-26. PubMed ID: 20225942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy.
    Rottinghaus EK; Ugbena R; Diallo K; Bassey O; Azeez A; Devos J; Zhang G; Aberle-Grasse J; Nkengasong J; Yang C
    Clin Infect Dis; 2012 Apr; 54(8):1187-95. PubMed ID: 22412066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges.
    Roberts T; Cohn J; Bonner K; Hargreaves S
    Clin Infect Dis; 2016 Apr; 62(8):1043-8. PubMed ID: 26743094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.
    Siedner MJ; Bwana MB; Moosa MS; Paul M; Pillay S; McCluskey S; Aturinda I; Ard K; Muyindike W; Moodley P; Brijkumar J; Rautenberg T; George G; Johnson B; Gandhi RT; Sunpath H; Marconi VC
    HIV Clin Trials; 2017 Jul; 18(4):149-155. PubMed ID: 28720039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral dynamics and viral load measurement: implications for therapy.
    Riddler SA; Mellors JW
    AIDS Clin Rev; 1997-1998; ():47-65. PubMed ID: 9305443
    [No Abstract]   [Full Text] [Related]  

  • 15. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings.
    Johannessen A; Trøseid M; Calmy A
    J Antimicrob Chemother; 2009 Dec; 64(6):1126-9. PubMed ID: 19776036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings.
    Lynen L; Van Griensven J; Elliott J
    Curr Opin HIV AIDS; 2010 Jan; 5(1):1-5. PubMed ID: 20046141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
    Tucker T; Yeats J
    S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
    [No Abstract]   [Full Text] [Related]  

  • 18. Dried blood spots in HIV monitoring: applications in resource-limited settings.
    Johannessen A
    Bioanalysis; 2010 Nov; 2(11):1893-908. PubMed ID: 21083497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated tiered service delivery model (ITSDM) based on local CD4 testing demands can improve turn-around times and save costs whilst ensuring accessible and scalable CD4 services across a national programme.
    Glencross DK; Coetzee LM; Cassim N
    PLoS One; 2014; 9(12):e114727. PubMed ID: 25490718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.
    Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H
    Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.